Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.68 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.68 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609720 | 0.93 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL17884952 | 0.93 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL6094605 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5656491 | 0.86 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5655329 | 0.86 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL7146555 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL7565522 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5656901 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL6351585 | 0.81 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL3678685 | 0.81 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133145-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-1751108-B1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8415354-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-04-09 | — | — | US | disclosed |
| US-8372841-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. | 2012-01-05 | — | — | US | disclosed |
| EP-2345640-A1 | Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7880001-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2010-09-02 | — | — | US | disclosed |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1751108-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005108368-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | CHRNB2 3251/4885CHRNA4 3842/4885CHRNA1 2651/4885 |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | CHRNB2 909/4885CHRNA4 1584/4885CHRNA1 1468/4885 |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | CHRNB2 909/4885CHRNA4 1584/4885CHRNA1 1468/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | CHRNB2 3251/4885CHRNA4 3842/4885CHRNA1 2651/4885 |
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | CHRNB2 3251/4885CHRNA4 3842/4885CHRNA1 2651/4885 |
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | CHRNB2 3251/4885CHRNA4 3842/4885CHRNA1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.